{"id":241,"date":"2020-06-04T00:32:48","date_gmt":"2020-06-04T00:32:48","guid":{"rendered":"https:\/\/mikemcmahon.info\/coach\/?p=241"},"modified":"2020-06-07T19:52:42","modified_gmt":"2020-06-07T19:52:42","slug":"crispr-theraputics","status":"publish","type":"post","link":"https:\/\/mikemcmahon.info\/coach\/crispr-theraputics\/","title":{"rendered":"Crispr Theraputics"},"content":{"rendered":"\n

One sentence overview<\/strong>:\u00a0Crispr Theraputics is a discovery-phase pharmaceutical Crispr working to develop therapies based on CRISPR\u2013Cas9 gene editing technology.<\/p>\n\n\n\n

Crispr Ticker :\u00a0\u00a0\u00a0\u00a0CRSP<\/p>\n\n\n\n

6\/3\/2020 Stock Price : $64.95<\/p>\n\n\n\n

6\/3\/2020 Market Cap : $4.0 billion<\/p>\n\n\n\n

Total Shares Outstanding Recent Quarterly Report :\u00a0 \u00a0 61 million shares<\/p>\n\n\n\n

<\/td>Jan 2020<\/strong><\/td>March Low<\/strong><\/td>Apr 30<\/strong><\/td>6\/3\/2020<\/strong><\/td>YTD %<\/strong><\/td><\/tr>
Crispr<\/td>$59<\/td>$34<\/td>$49<\/td>$65<\/td>10%<\/td><\/tr>
S&P 500<\/td>3231<\/td>2237<\/td>2912<\/td>3123<\/td>-4%<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Crispr Investor Relations Page<\/strong>

http:\/\/ir.crisprtx.com\/investor-overview<\/a>

Crispr SEC Page<\/strong>

https:\/\/www.sec.gov\/cgi-bin\/browse-edgar?CIK=crsp&owner=\u2026<\/a>

Crispr Glassdoor Ratings<\/strong>
https:\/\/www.glassdoor.com\/Overview\/Working-at-CRISPR-Therape\u2026<\/a><\/p>\n\n\n\n

Crispr Overview<\/strong><\/p>\n\n\n\n

Crispr Medicine is one of three companies (Editas Medicine EDIT and Intellia Theraputics NTLA) using Crispr-Cas9 technology. For an explanation for Crispr-Cas9 technology go here:<\/p>\n\n\n\n

https:\/\/www.livescience.com\/58790-crispr-explained.html<\/a><\/p>\n\n\n\n

Products<\/strong><\/p>\n\n\n\n

The next slides are from a June 2020 presentation from their Investor Relations. It should be pointed out Crispr products presented in the slides are at least 5 years away from the commercial market. Clinical trials typically take about 5 years to complete.<\/p>\n\n\n\n

\"\"<\/figure>\n\n\n\n
\"\"<\/figure>\n\n\n\n

Financials<\/strong><\/p>\n\n\n\n

\"\"<\/figure>\n\n\n\n
\"\"<\/figure>\n\n\n\n
\"\"<\/figure>\n\n\n\n

Competition<\/strong><\/p>\n\n\n\n

Editas Medicine EDIT and Intellia Theraputics NTLA are the two other companies using Crispr-Cas9 technology.<\/p>\n\n\n\n

Future Outlook<\/strong><\/p>\n\n\n\n

Crispr work on sickle cell anemia is promising. However, clinical trials have long time horizon and FDA approval will take years.<\/p>\n\n\n\n

Risks<\/strong><\/p>\n\n\n\n

Unsuccessful clinical trials would result in starting over. To maintain an ongoing entity, additional stock offerings will be done and therefore dilute current shareholder positions.<\/p>\n\n\n\n

Disclaimer: I do not have any formal recommendation for or against this stock, so don\u2019t buy or sell stocks based solely on what you read.<\/em><\/p>\n\n\n\n

Interested in receiving a weekly recap of reviewed stocks? Sign up.<\/p>\n\n\n\n